Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

The National Institute for Health and Care Excellence (Nice) is concerned about the number of people regaining weight after ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

People coming off obesity jabs like Wegovy and Mounjaro should have check-ups for at least a year to make sure they don't ...

I've been paying for Mounjaro for more than a year, and have lost a fair bit of weight. Now it's available on the NHS, will I ...

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

Experts say NHS patients should be monitored for at least a year after treatment ends, with tailored support provided if ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

Research shows that many people regain weight after stopping treatment if they are not supported. Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, ...